20 results on '"Wöll, E."'
Search Results
2. Multizentrische, retrospektive Kohortenstudie zur Erhebung der Inzidenz der Medikamenten-assoziierten Kiefernekrose bei Patient:innen mit primär oder sekundär ossär metastasiertem Mammakarzinom
- Author
-
Baumgart, F, additional, Egle, D, additional, Ritter, M, additional, Marth, C, additional, Laimer, J, additional, Walch, B, additional, Iannetti, C, additional, Wöll, E, additional, Zabernigg, A, additional, Pinzger, G, additional, Volgger, B, additional, Andraschofsky, T O, additional, Markl, A, additional, Hubalek, M, additional, Siebert, U, additional, Arvandi, M, additional, and Brunner, C, additional
- Published
- 2023
- Full Text
- View/download PDF
3. S179: RANDOMIZED COMPARISON BETWEEN KRD AND KTD INDUCTION, FOLLOWED BY K MAINTENANCE OR OBSERVATION IN TRANSPLANT NON-ELIGIBLE PATIENTS WITH NDMM (AGMT-MM02 TRIAL)
- Author
-
Ludwig, H., primary, Melchardt, T., additional, Sormann, S., additional, Zojer, N., additional, Andel, J., additional, Hartmann, B., additional, Tinchon, C., additional, Gunsilius, E., additional, Podar, K., additional, Egle, A., additional, Willenbacher, W., additional, Wöll, E., additional, Schreder, M., additional, Ruckser, R., additional, Bozic, B, additional, Krauth, M.-T., additional, Petzer, A., additional, Schmitt, C, additional, Machherndl-Spandl, S., additional, Agis, H., additional, Fillitz, M., additional, Pönisch, W., additional, Knop, S., additional, Paiva, B., additional, and Greil, R., additional
- Published
- 2022
- Full Text
- View/download PDF
4. Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study.
- Author
-
Brunner C, Arvandi M, Marth C, Egle D, Baumgart F, Emmelheinz M, Walch B, Lercher J, Iannetti C, Wöll E, Pechlaner A, Zabernigg A, Volgger B, Castellan M, Andraschofsky OT, Markl A, Hubalek M, Schnallinger M, Puntscher S, Siebert U, Schönherr S, Forer L, Bruckmoser E, and Laimer J
- Abstract
Purpose: Medication-related osteonecrosis of the jaw (MRONJ) is one of the most important toxicities of antiresorptive therapy, which is standard practice for patients with breast cancer and bone metastases. However, the population-based incidence of MRONJ is not well established. We therefore performed a retrospective multicenter study to assess the incidence for a whole Austrian federal state (Tyrol)., Materials and Methods: This retrospective multicenter study was conducted between 2000 and 2020 at all nine breast centers across Tyrol, Austria. Using the cancer registry, the total Tyrolean population was screened for all patients with breast cancer. All patients with breast cancer and bone metastases receiving antiresorptive therapy were finally included in the study., Results: From 8,860 patients initially screened, 639 individuals were eligible and included in our study. Patients received antiresorptive therapy once per month without de-escalation of therapy. MRONJ was diagnosed in 56 (8.8%, 95% CI, 6.6 to 11.0) patients. The incidence of MRONJ was 11.6% (95% CI, 8.0 to 15.3) in individuals treated with denosumab only, 2.8% (95% CI, 0.7 to 4.8) in those treated with bisphosphonates only, and 16.3% (95% CI, 8.8 to 23.9) in the group receiving bisphosphonates followed by denosumab. Individuals developed MRONJ significantly earlier when treated with denosumab. Time to MRONJ after treatment initiation was 4.6 years for individuals treated with denosumab only, 5.1 years for individuals treated with bisphosphonates only, and 8.4 years for individuals treated with both consecutively., Conclusion: MRONJ incidence in breast cancer patients with bone metastases was found to be considerably higher, especially for patients receiving denosumab, when compared with available data in the literature. Additionally, patients treated with denosumab developed MRONJ significantly earlier.
- Published
- 2024
- Full Text
- View/download PDF
5. QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study.
- Author
-
Ludwig H, Melchardt T, Schweitzer I, Sormann S, Schreder M, Andel J, Hartmann B, Zojer N, Schöffmann L, Gunsilius E, Podar K, Egle A, Willenbacher W, Wöll E, Ruckser R, Bozic B, Krauth MT, Petzer A, Schmitt C, Machherndl-Spandl S, Agis H, Fillitz M, Wang SY, Knop S, and Greil R
- Abstract
Understanding the impact of induction and maintenance therapy on patients' quality of life (QoL) is important for treatment selection. This study aims to compare patient-reported QoL between patients treated with KTd or KRd induction therapy and K maintenance therapy or observation. QoL was assessed using the EORTC QOL-C 30 and QOL-MY20 questionnaires in the AGMT-02 study, in which 123 patients with newly diagnosed transplant ineligible multiple myeloma were randomized to nine cycles of either KTd or KRd induction therapy, followed by 12 cycles of K maintenance therapy, or observation. Longitudinal assessments showed statistically significant improvements in global health-related QoL, various disease symptoms and pain for both treatment regimens. KTd improved insomnia and fatigue, and KRd improved physical functioning. Cross-sectional comparisons indicated a "slight" superiority of KTd over KRd in several scales, with the exception of higher neuropathy scores with KTd. During maintenance, longitudinal comparisons showed no statistically significant changes. Cross-sectional comparisons revealed a "slight" improvement in cognitive functioning during carfilzomib therapy, but a worsening in most other QoL scales. Induction therapy led to improvements in most QoL items, while maintenance therapy with K maintenance was associated with "slight" or "moderate" impairments in several QoL scales compared with the observation group., Competing Interests: The study was supported by AMGEN which provided support for the conduct and analysis of the trial, and by the Austrian Forum against Cancer which supported in part the scientific assistance of HL. HL declares receiving honoraria for lectures or advisory boards from Janssen, BMS, Takeda, Pfizer, Sanofi, and Stem line and research support from AMGEN and Sanofi. TM received honoraria from AbbVie and BMS. MS received honoraria from Janssen, AbbVie, BMS, and Pfizer. BH received honoraria from BMS, Amgen, AbbVie, and Janssen‐Cilag. KP received research funding and honoraria for consultancy from Amgen, BMS, Janssen, and Roche. WW is an employee of syndena GmbH and received research funding from Amgen, Takeda, BMS‐Celgene, Janssen‐Cilag, Novartis, Roche, Sanofi, and oncotyrol and received honoraria for participation in steering and safety committees from Amgen, BMS‐Celgene, and Morphosys and received honoraria for consultancy from Amgen, Takeda, BMS‐Celgene, EUSA Pharma, Gilead, AbbVie, Janssen‐Cilag, GSK, Incyte, Kite, Novartis, Morphosys, Merck, Pfizer, Roche, Sandoz, and Sanofi, and received honoraria from Fujimoto and Myelom‐ und Lymphomselbsthilfe. MTK received research funding from Janssen and honoraria from GSK, Sanofi, Pfizer, Janssen, Amgen, BMS‐Celgene, and Takeda. AP received honoraria for participation in advisory boards from Novartis, Kite‐Gilead, Amgen, Celgene, Janssen, Roche, Sandoz, AstraZeneca, AbbVie, Takeda, Sanofi, Pfizer, Saegen, Daiichi Sankyo, and received travel support from Kite‐Gilead, Janssen, Roche, AstraZeneca, Pfizer, and Daiichi Sankyo. CS received research funding from AstraZeneca, Janssen‐Cilag, and Roche, and received honoraria for consultancy from AbbVie, AstraZeneca, BMS‐Celgene, Janssen‐Cilag, Roche, and Takeda. SMS received honoraria for consultancy from Jazz Pharmaceuticals, Novartis, Amgen, BMS, and Gilead. HA received research funding from Janssen and received honoraria from Janssen, Amgen, BMS, and Takeda. SK received honoraria from Amgen, BMS‐Celgene, and Sanofi, and received travel grants from BMS and Sobi. RG received research funding, travel support, and honoraria for consultancy and participation in advisory boards from AbbVie, Takeda, Daiichi Sankyo, Gilead, MSD Merck, BMS‐Celgene, Novartis, AstraZeneca, Janssen‐Cilag, and Hoffmann‐La Roche. The remaining authors declare no conflict of interest., (© 2024 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
6. Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma.
- Author
-
Ludwig H, Melchardt T, Sormann S, Schreder M, Andel J, Hartmann B, Tinchon C, Zojer N, Gunsilius E, Podar K, Egle A, Willenbacher W, Wöll E, Ruckser R, Bozic B, Krauth MT, Petzer A, Schmitt C, Machherndl-Spandl S, Agis H, Fillitz M, Wang SY, Zabernigg A, Knop S, Paiva B, and Greil R
- Subjects
- Humans, Antineoplastic Combined Chemotherapy Protocols adverse effects, Dexamethasone therapeutic use, Induction Chemotherapy, Lenalidomide therapeutic use, Multiple Myeloma diagnosis, Multiple Myeloma drug therapy
- Abstract
Randomized comparison between KTd and KRd induction followed by second randomization to carfilzomib in transplant-ineligable patients with newly diagnosed multiple myeloma., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
7. German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer.
- Author
-
Lordick F, Al-Batran SE, Arnold D, Borner M, Bruns CJ, Eisterer W, Faber G, Gockel I, Köberle D, Lorenzen S, Möhler M, Pritzkuleit R, Stahl M, Thuss-Patience P, Wöll E, Zander T, and Maschmeyer G
- Subjects
- Humans, Austria, Medical Oncology, Stomach Neoplasms therapy
- Abstract
The updated edition of the German, Austrian and Swiss Guidelines for Systemic Treatment of Gastric Cancer was completed in August 2023, incorporating new evidence that emerged after publication of the previous edition. It consists of a text-based "Diagnosis" part and a "Therapy" part including recommendations and treatment algorithms. The treatment part includes a comprehensive description regarding perioperative and palliative systemic therapy for gastric cancer and summarizes recommended standard of care for surgery and endoscopic resection. The guidelines are based on a literature search and evaluation by a multidisciplinary panel of experts nominated by the hematology and oncology scientific societies of the three involved countries., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
8. Distinct smell and taste disorder phenotype of post-acute COVID-19 sequelae.
- Author
-
Rass V, Tymoszuk P, Sahanic S, Heim B, Ausserhofer D, Lindner A, Kofler M, Mahlknecht P, Boehm A, Hüfner K, Pizzini A, Sonnweber T, Kurz K, Pfeifer B, Kiechl S, Peball M, Kindl P, Putnina L, Fava E, Djamshidian A, Huber A, Wiedermann CJ, Sperner-Unterweger B, Wöll E, Beer R, Schiefecker AJ, Bellmann-Weiler R, Bachler H, Tancevski I, Pfausler B, Piccoliori G, Seppi K, Weiss G, Löffler-Ragg J, and Helbok R
- Subjects
- Female, Humans, Quality of Life, SARS-CoV-2, Smell, Taste, Taste Disorders epidemiology, Taste Disorders etiology, COVID-19 complications, COVID-19 epidemiology, Olfaction Disorders epidemiology, Olfaction Disorders etiology, Olfaction Disorders diagnosis
- Abstract
Purpose: Olfactory dysfunction (OD) commonly accompanies coronavirus disease 2019 (COVID-19). We investigated the kinetics of OD resolution following SARS-CoV-2 infection (wild-type and alpha variant) and its impact on quality of life, physical and mental health., Methods: OD prevalence was assessed in an ambulatory COVID-19 survey (n = 906, ≥ 90 days follow-up) and an observational cohort of ambulatory and hospitalized individuals (n = 108, 360 days follow-up). Co-occurrence of OD with other symptoms and effects on quality of life, physical and mental health were analyzed by multi-dimensional scaling, association rule mining and semi-supervised clustering., Results: Both in the ambulatory COVID-19 survey study (72%) and the observational ambulatory and hospitalized cohort (41%) self-reported OD was frequent during acute COVID-19. Recovery from self-reported OD was slow (survey: median 28 days, observational cohort: 90 days). By clustering of the survey data, we identified a predominantly young, female, comorbidity-free group of convalescents with persistent OD and taste disorders (median recovery: 90 days) but low frequency of post-acute fatigue, respiratory or neurocognitive symptoms. This smell and taste disorder cluster was characterized by a high rating of physical performance, mental health, and quality of life as compared with convalescents affected by prolonged fatigue or neurocognitive complaints., Conclusion: Our results underline the heterogeneity of post-acute COVID-19 sequelae calling for tailored management strategies. The persistent smell and taste disorder phenotype is characterized by good clinical, physical, and mental recovery and may pose a minor challenge for public health., Study Registration: ClinicalTrials.gov: NCT04661462 (survey study), NCT04416100 (observational cohort)., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
9. Systemic treatment of patients with locally advanced or metastatic cholangiocarcinoma - an Austrian expert consensus statement.
- Author
-
Taghizadeh H, Djanani A, Eisterer W, Gerger A, Gruenberger B, Gruenberger T, Rumpold H, Weiss L, Winder T, Wöll E, and Prager GW
- Abstract
Locally advanced or metastatic cholangiocarcinoma is an aggressive carcinoma with a dismal prognosis. For the first-line treatment of locally advanced or metastatic cholangiocarcinoma, cisplatin/gemcitabine has been the standard of care for more than 10 years. Its combination with the immune checkpoint inhibitor durvalumab resulted in an efficiency improvement in the phase III setting. Regarding the use of chemotherapy in the second line, positive phase III data could only be generated for FOLFOX. The evidence base for nanoliposomal irinotecan (Nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin (LV) is contradictory. After the failure of first-line treatment, targeted therapies can be offered if the molecular targets microsatellite instability-high (MSI-H), IDH1, FGFR2, BRAF V600E, and NTRK are detected. These targeted agents are generally preferable to second-line chemotherapy. Broad molecular testing should be performed, preferably from tumor tissue, at the initiation of first-line therapy to timely identify potential molecular targets., Competing Interests: The publication of this consensus statement was supported by AstraZeneca Österreich GmbH, Incyte Biosciences Austria GmbH, and Servier Austria GmbH., (Copyright © 2023 Taghizadeh, Djanani, Eisterer, Gerger, Gruenberger, Gruenberger, Rumpold, Weiss, Winder, Wöll and Prager.)
- Published
- 2023
- Full Text
- View/download PDF
10. Treatment Algorithm for Patients With Gastric Adenocarcinoma: Austrian Consensus on Systemic Therapy - An Update.
- Author
-
Wöll E, Amann A, Eisterer W, Gerger A, Grünberger B, Rumpold H, Weiss L, Winder T, Greil R, and Prager GW
- Subjects
- Humans, Austria, Consensus, Algorithms, Esophagogastric Junction pathology, Receptor, ErbB-2 metabolism, Stomach Neoplasms drug therapy, Stomach Neoplasms genetics, Adenocarcinoma drug therapy, Adenocarcinoma genetics, Esophageal Neoplasms pathology
- Abstract
Over the last decade, therapeutic options for patients with gastric cancer have improved significantly. However, despite these recent advances, mortality is still substantial. Surgery and chemotherapy represent the cornerstones of patient management. Immune checkpoint inhibitors as well as targeted treatments such as HER2-directed therapies and antiangiogenic agents contribute to improved patient prognosis. Herein, we present the updated version of an Austrian consensus on the systemic treatment of patients with gastric adenocarcinoma and adenocarcinoma of the lower gastroesophageal junction, including those with human epidermal growth receptor 2 (HER2) overexpression, microsatellite instability, programmed death-ligand 1 (PD-L1)-positive disease, and claudin 18.2 positivity. The consensus considers the curative setting as well as first-line and later-line systemic treatment options in advanced disease. For HER2-positive disease, HER2 testing is discussed in addition to a review of first-line and later-line therapies. Potential future therapies are also listed, with a focus on targeted [e.g., fibroblast growth factor receptor 2 (FGRF2)-directed] treatments that might provide a further step forward in the management of patients with gastric cancer., (Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
11. Stroke Care Pathway ensures high-quality stroke management in the COVID-19 pandemic.
- Author
-
Mayer-Suess L, Ter Telgte A, Praxmarer S, Willeit J, Wöll E, Geley T, Rinner H, Knoflach M, and Kiechl S
- Subjects
- Humans, Pandemics, SARS-CoV-2, Retrospective Studies, Prospective Studies, Critical Pathways, COVID-19, Stroke epidemiology
- Abstract
The aim of our study was to assess whether a well-established federal state-wide Stroke Care Pathway delivering high quality stroke care can cope with the COVID-19 pandemic and associated measures to contain the virus spread. The retrospective analysis is based on a prospective, quality-controlled, population-based registry of all stroke patients in the Tyrol, a federal state of Austria and one of the early hot-spots of COVID-19 in Europe. Patient characteristics, pre-hospital management, intra-hospital management and post-hospital were analysed. All residents of the Tyrol suffering ischemic stroke in 2020 (n = 1160) and four pre-COVID-19 years (n = 4321) were evaluated. In 2020, the annual number of stroke patients was the highest in this population-based registry. When local hospitals were overwhelmed with SARS-CoV-2-patients, stroke subjects were temporarily allocated to the comprehensive stroke centre. Stroke severity, quality metrics of stroke management, serious complications, and post-stroke mortality did not differ between 2020 and the four comparator years. Notably, iv. thrombolysis-rate was similar (19.9% versus 17.4%, P = 0.25) and endovascular stroke treatment even better (5.9% versus 3.9%, P = 0.003) but resources for in-patient rehabilitation were limited (25.8% versus 29.8%, P = 0.009). Concluding, a well-established Stroke Care Pathway was able to maintain high-quality acute stroke care even when challenged by a global pandemic., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
12. "Beyond the guidelines" - Deviations in adherence to infection control measures in Tyrolean hospitals, Austria.
- Author
-
Berktold M, Fuchs S, Kuppelwieser B, Ulmer H, Kettner M, Thummer L, Wöll E, and Lass-Flörl C
- Subjects
- Humans, Austria, Infection Control, Hospitals, Guideline Adherence, Cross Infection prevention & control, Physicians
- Abstract
Background: Hospital-acquired infections represent increasing problems in health-care facilities worldwide. Adequate infection control measures are key elements in preventing those infections. Expert societies have published recommendations that help to reduce Hospital-acquired infections., Methods: In November 2019, a questionnaire-based point-prevalence survey, eliciting the adherence of 14 Tyrolean hospitals to the recommendations of the Centers of Disease Control and Prevention (CDC) was performed. Additionally, standard infection control measures performed by different medical (clinical and infection control specialists) disciplines as well as the performed infection control measures of nurses and physicians were compared., Results: The survey revealed varying adherence to CDC-recommendations of different medical disciplines, with highest congruence by the infection control specialists and lower congruencies by all surveyed clinical disciplines. Concordance rate between nurses and physicians was high., Discussion: Explanations for the varying congruencies of clinical disciplines on the one hand and the infection control specialists on the other hand may be versatile. Possible lacks of knowledge about the required hygiene measures should be taken into account., Conclusions: The present survey showed moderate adherence of Tyrolean hospitals to the recommendations provided by CDC, however with noticeable differences between different medical disciplines. Nurses and doctors in most cases reported identically., (Copyright © 2022 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
13. COVID-19 and its continuing burden after 12 months: a longitudinal observational prospective multicentre trial.
- Author
-
Sahanic S, Tymoszuk P, Luger AK, Hüfner K, Boehm A, Pizzini A, Schwabl C, Koppelstätter S, Kurz K, Asshoff M, Mosheimer-Feistritzer B, Coen M, Pfeifer B, Rass V, Egger A, Hörmann G, Sperner-Unterweger B, Helbok R, Wöll E, Weiss G, Widmann G, Tancevski I, Sonnweber T, and Löffler-Ragg J
- Abstract
Background: Recovery trajectories from coronavirus disease 2019 (COVID-19) call for longitudinal investigation. We aimed to characterise the kinetics and status of clinical, cardiopulmonary and mental health recovery up to 1 year following COVID-19., Methods: Clinical evaluation, lung function testing (LFT), chest computed tomography (CT) and transthoracic echocardiography were conducted at 2, 3, 6 and 12 months after disease onset. Submaximal exercise capacity, mental health status and quality of life were assessed at 12 months. Recovery kinetics and patterns were investigated by mixed-effect logistic modelling, correlation and clustering analyses. Risk of persistent symptoms and cardiopulmonary abnormalities at the 1-year follow-up were modelled by logistic regression., Findings: Out of 145 CovILD study participants, 108 (74.5%) completed the 1-year follow-up (median age 56.5 years; 59.3% male; 24% intensive care unit patients). Comorbidities were present in 75% (n=81). Key outcome measures plateaued after 180 days. At 12 months, persistent symptoms were found in 65% of participants; 33% suffered from LFT impairment; 51% showed CT abnormalities; and 63% had low-grade diastolic dysfunction. Main risk factors for cardiopulmonary impairment included pro-inflammatory and immunological biomarkers at early visits. In addition, we deciphered three recovery clusters separating almost complete recovery from patients with post-acute inflammatory profile and an enrichment in cardiopulmonary residuals from a female-dominated post-COVID-19 syndrome with reduced mental health status., Conclusion: 1 year after COVID-19, the burden of persistent symptoms, impaired lung function, radiological abnormalities remains high in our study population. Yet, three recovery trajectories are emerging, ranging from almost complete recovery to post-COVID-19 syndrome with impaired mental health., Competing Interests: Conflict of interest: P. Tymoszuk owns the Data Analytics as a Service data science enterprise and is (from May 2021 on) a freelance data scientist working in his own enterprise; he received honoraria for the statistical analysis of the CovILD study. All other authors have no conflict of interest related to this study to declare., (Copyright ©The authors 2023.)
- Published
- 2023
- Full Text
- View/download PDF
14. Pulmonary recovery from COVID-19 in patients with metabolic diseases: a longitudinal prospective cohort study.
- Author
-
Sonnweber T, Grubwieser P, Pizzini A, Boehm A, Sahanic S, Luger A, Schwabl C, Widmann G, Egger A, Hoermann G, Wöll E, Puchner B, Kaser S, Theurl I, Nairz M, Tymoszuk P, Weiss G, Joannidis M, Löffler-Ragg J, and Tancevski I
- Subjects
- Humans, Prospective Studies, SARS-CoV-2, Lung diagnostic imaging, COVID-19 complications, Metabolic Diseases complications, Dyslipidemias complications
- Abstract
The severity of coronavirus disease 2019 (COVID-19) is related to the presence of comorbidities including metabolic diseases. We herein present data from the longitudinal prospective CovILD trial, and investigate the recovery from COVID-19 in individuals with dysglycemia and dyslipidemia. A total of 145 COVID-19 patients were prospectively followed and a comprehensive clinical, laboratory and imaging assessment was performed at 60, 100, 180, and 360 days after the onset of COVID-19. The severity of acute COVID-19 and outcome at early post-acute follow-up were significantly related to the presence of dysglycemia and dyslipidemia. Still, at long-term follow-up, metabolic disorders were not associated with an adverse pulmonary outcome, as reflected by a good recovery of structural lung abnormalities in both, patients with and without metabolic diseases. To conclude, dyslipidemia and dysglycemia are associated with a more severe course of acute COVID-19 as well as delayed early recovery but do not impair long-term pulmonary recovery., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
15. Austrian Society for Hematology and Medical Oncology (OeGHO) spring meeting 2023.
- Author
-
Wöll E
- Abstract
Competing Interests: Conflict of interestE. Wöll declares that he has no competing interests.
- Published
- 2023
- Full Text
- View/download PDF
16. Chest CT of Lung Injury 1 Year after COVID-19 Pneumonia: The CovILD Study.
- Author
-
Luger AK, Sonnweber T, Gruber L, Schwabl C, Cima K, Tymoszuk P, Gerstner AK, Pizzini A, Sahanic S, Boehm A, Coen M, Strolz CJ, Wöll E, Weiss G, Kirchmair R, Feuchtner GM, Prosch H, Tancevski I, Löffler-Ragg J, and Widmann G
- Subjects
- Female, Humans, Lung diagnostic imaging, Male, Middle Aged, Prospective Studies, SARS-CoV-2, Tomography, X-Ray Computed methods, COVID-19 diagnostic imaging, Lung Injury
- Abstract
Background The long-term pulmonary sequelae of COVID-19 is not well known. Purpose To characterize patterns and rates of improvement of chest CT abnormalities 1 year after COVID-19 pneumonia. Materials and Methods This was a secondary analysis of a prospective, multicenter observational cohort study conducted from April 29 to August 12, 2020, to assess pulmonary abnormalities at chest CT approximately 2, 3, and 6 months and 1 year after onset of COVID-19 symptoms. Pulmonary findings were graded for each lung lobe using a qualitative CT severity score (CTSS) ranging from 0 (normal) to 25 (all lobes involved). The association of demographic and clinical factors with CT abnormalities after 1 year was assessed with logistic regression. The rate of change of the CTSS at follow-up CT was investigated by using the Friedmann test. Results Of 142 enrolled participants, 91 underwent a 1-year follow-up CT examination and were included in the analysis (mean age, 59 years ± 13 [SD]; 35 women [38%]). In 49 of 91 (54%) participants, CT abnormalities were observed: 31 of 91 (34%) participants showed subtle subpleural reticulation, ground-glass opacities, or both, and 18 of 91 (20%) participants had extensive ground-glass opacities, reticulations, bronchial dilation, microcystic changes, or a combination thereof. At multivariable analysis, age of more than 60 years (odds ratio [OR], 5.8; 95% CI: 1.7, 24; P = .009), critical COVID-19 severity (OR, 29; 95% CI: 4.8, 280; P < .001), and male sex (OR, 8.9; 95% CI: 2.6, 36; P < .001) were associated with persistent CT abnormalities at 1-year follow-up. Reduction of CTSS was observed in participants at subsequent follow-up CT ( P < .001); during the study period, 49% (69 of 142) of participants had complete resolution of CT abnormalities. Thirty-one of 49 (63%) participants with CT abnormalities showed no further improvement after 6 months. Conclusion Long-term CT abnormalities were common 1 year after COVID-19 pneumonia. © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Leung in this issue.
- Published
- 2022
- Full Text
- View/download PDF
17. The Impact of Iron Dyshomeostasis and Anaemia on Long-Term Pulmonary Recovery and Persisting Symptom Burden after COVID-19: A Prospective Observational Cohort Study.
- Author
-
Sonnweber T, Grubwieser P, Sahanic S, Böhm AK, Pizzini A, Luger A, Schwabl C, Koppelstätter S, Kurz K, Puchner B, Sperner-Unterweger B, Hüfner K, Wöll E, Nairz M, Widmann G, Tancevski I, Löffler-Ragg J, and Weiss G
- Abstract
Coronavirus disease 2019 (COVID-19) is frequently associated with iron dyshomeostasis. The latter is related to acute disease severity and COVID-19 convalescence. We herein describe iron dyshomeostasis at COVID-19 follow-up and its association with long-term pulmonary and symptomatic recovery. The prospective, multicentre, observational cohort study "Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection (CovILD)" encompasses serial extensive clinical, laboratory, functional and imaging evaluations at 60, 100, 180 and 360 days after COVID-19 onset. We included 108 individuals with mild-to-critical acute COVID-19, whereas 75% presented with severe acute disease. At 60 days post-COVID-19 follow-up, hyperferritinaemia (35% of patients), iron deficiency (24% of the cohort) and anaemia (9% of the patients) were frequently found. Anaemia of inflammation (AI) was the predominant feature at early post-acute follow-up, whereas the anaemia phenotype shifted towards iron deficiency anaemia (IDA) and combinations of IDA and AI until the 360 days follow-up. The prevalence of anaemia significantly decreased over time, but iron dyshomeostasis remained a frequent finding throughout the study. Neither iron dyshomeostasis nor anaemia were related to persisting structural lung impairment, but both were associated with impaired stress resilience at long-term COVID-19 follow-up. To conclude, iron dyshomeostasis and anaemia are frequent findings after COVID-19 and may contribute to its long-term symptomatic outcome.
- Published
- 2022
- Full Text
- View/download PDF
18. Investigating phenotypes of pulmonary COVID-19 recovery: A longitudinal observational prospective multicenter trial.
- Author
-
Sonnweber T, Tymoszuk P, Sahanic S, Boehm A, Pizzini A, Luger A, Schwabl C, Nairz M, Grubwieser P, Kurz K, Koppelstätter S, Aichner M, Puchner B, Egger A, Hoermann G, Wöll E, Weiss G, Widmann G, Tancevski I, and Löffler-Ragg J
- Subjects
- Adult, Aged, COVID-19 epidemiology, COVID-19 rehabilitation, Female, Follow-Up Studies, Humans, Intensive Care Units, Logistic Models, Longitudinal Studies, Lung Diseases diagnosis, Male, Middle Aged, Phenotype, Prospective Studies, Risk Factors, SARS-CoV-2, Tomography, X-Ray Computed methods, COVID-19 therapy, Lung Diseases epidemiology, Lung Diseases physiopathology
- Abstract
Background: The optimal procedures to prevent, identify, monitor, and treat long-term pulmonary sequelae of COVID-19 are elusive. Here, we characterized the kinetics of respiratory and symptom recovery following COVID-19., Methods: We conducted a longitudinal, multicenter observational study in ambulatory and hospitalized COVID-19 patients recruited in early 2020 (n = 145). Pulmonary computed tomography (CT) and lung function (LF) readouts, symptom prevalence, and clinical and laboratory parameters were collected during acute COVID-19 and at 60, 100, and 180 days follow-up visits. Recovery kinetics and risk factors were investigated by logistic regression. Classification of clinical features and participants was accomplished by unsupervised and semi-supervised multiparameter clustering and machine learning., Results: At the 6-month follow-up, 49% of participants reported persistent symptoms. The frequency of structural lung CT abnormalities ranged from 18% in the mild outpatient cases to 76% in the intensive care unit (ICU) convalescents. Prevalence of impaired LF ranged from 14% in the mild outpatient cases to 50% in the ICU survivors. Incomplete radiological lung recovery was associated with increased anti-S1/S2 antibody titer, IL-6, and CRP levels at the early follow-up. We demonstrated that the risk of perturbed pulmonary recovery could be robustly estimated at early follow-up by clustering and machine learning classifiers employing solely non-CT and non-LF parameters., Conclusions: The severity of acute COVID-19 and protracted systemic inflammation is strongly linked to persistent structural and functional lung abnormality. Automated screening of multiparameter health record data may assist in the prediction of incomplete pulmonary recovery and optimize COVID-19 follow-up management., Funding: The State of Tyrol (GZ 71934), Boehringer Ingelheim/Investigator initiated study (IIS 1199-0424)., Clinical Trial Number: ClinicalTrials.gov: NCT04416100., Competing Interests: TS, SS, AB, AP, AL, CS, MN, PG, KK, SK, MA, BP, AE, GH, EW, GW, GW, IT, JL No competing interests declared, PT owns his own business, Data Analytics as a Service Tirol, for which he performs freelance data science work. Has also received an honorarium for the study data management, curation and analysis and minor manuscript work. The author has no other competing interests to declare, (© 2022, Sonnweber et al.)
- Published
- 2022
- Full Text
- View/download PDF
19. Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort.
- Author
-
Schlintl V, Huemer F, Rinnerthaler G, Melchardt T, Winder T, Reimann P, Riedl J, Amann A, Eisterer W, Romeder F, Piringer G, Ilhan-Mutlu A, Wöll E, Greil R, and Weiss L
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized therapeutic use, Austria, Esophagogastric Junction pathology, Female, Humans, Immunotherapy, Male, Middle Aged, Nivolumab therapeutic use, Progression-Free Survival, Retrospective Studies, Esophageal Neoplasms drug therapy, Esophageal Neoplasms mortality, Esophageal Neoplasms pathology, Immune Checkpoint Inhibitors therapeutic use, Stomach Neoplasms drug therapy, Stomach Neoplasms mortality, Stomach Neoplasms pathology
- Abstract
Background: Safety and efficacy of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction (GEJ) cancer could be demonstrated in predominantly Asian cohorts, whereas data in Western patients outside of clinical trials are vastly missing., Methods: In this multi-institutional retrospective analysis conducted at nine oncologic centers in Austria, we tried to assess feasibility of checkpoint inhibitors in advanced gastric/GEJ cancer in a real-world Western cohort., Results: In total, data from 50 patients with metastatic gastric/GEJ cancer who received nivolumab or pembrolizumab in a palliative setting between November 2015 and April 2020 have been evaluated. The median number of previous palliative therapy lines was two. The median progression-free survival (PFS) and overall survival (OS) were 2.1 (95% CI: 1.4-2.8) and 6.3 (95% CI: 3.3-9.3) months, respectively. There was no statistically significant difference in median OS according to microsatellite or PD-L1 status. However, a trend towards prolonged PFS and OS for the microsatellite instability high subgroup could be observed. Patients with an ECOG Performance Status (PS) ≥ 2 displayed a significantly worse outcome than those with an ECOG PS ≤ 1 (p = .03). Only one patient discontinued immunotherapy due to treatment-related toxicity., Conclusions: Our results support feasibility of nivolumab and pembrolizumab in pre-treated patients with metastatic gastric and GEJ cancer in a Western real-world cohort. Further phase II/III studies are needed to confirm clinical efficacy., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
20. Muscle involvement in SARS-CoV-2 infection.
- Author
-
Pitscheider L, Karolyi M, Burkert FR, Helbok R, Wanschitz JV, Horlings C, Pawelka E, Omid S, Traugott M, Seitz T, Zoufaly A, Lindeck-Pozza E, Wöll E, Beer R, Seiwald S, Bellmann-Weiler R, Hegen H, and Löscher WN
- Subjects
- Humans, Male, Muscles, Pandemics, SARS-CoV-2, COVID-19, Influenza, Human complications, Influenza, Human epidemiology
- Abstract
Background and Purpose: Since the outbreak of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, several reports indicated neurological involvement in COVID-19 disease. Muscle involvement has also been reported as evidenced by creatine kinase (CK) elevations and reports of myalgia., Methods: Creatine kinase, markers of inflammation, pre-existing diseases and statin use were extracted from records of Austrian hospitalised COVID-19 patients. Disease severity was classified as severe in case of intensive care unit (ICU) admission or mortality. COVID-19 patients were additionally compared to an historical group of hospitalised influenza patients., Results: Three hundred fifty-one patients with SARS-CoV-2 and 258 with influenza were included in the final analysis. CK was elevated in 27% of COVID-19 and in 28% of influenza patients. CK was higher in severe COVID-19 as were markers of inflammation. CK correlated significantly with inflammation markers, which had an independent impact on CK when adjusted for demographic variables and disease severity. Compared to influenza patients, COVID-19 patients were older, more frequently male, had more comorbidities, and more frequently had a severe disease course. Nevertheless, influenza patients had higher baseline CK than COVID-19, and 35.7% of intensive care unit (ICU)-admitted patients had CK levels >1,000 U/L compared to only 4.7% of ICU-admitted COVID-19 patients., Conclusions: HyperCKemia occurs in a similar frequency in COVID-19 and influenza infection. CK levels were lower in COVID-19 than in influenza in mild and severe disease. CK levels strongly correlate with disease severity and markers of inflammation. To date, it remains unclear whether hyperCKemia is due to a virus-triggered inflammatory response or direct muscle toxicity., (© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.